HPHela-Felicitas Petereit

Hela-Felicitas Petereit

*This is an algorithmically generated author record based on publicly available information.

Hela-Felicitas Petereit has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 4 Praxisbeispiele für gezielte Stufendiagnostik

    by Matthias Imöhl, Axel Stachon, Arnold von Eckardstein, Elisabeth Minder, Max G. Bachem, Thomas Seufferlein, Marco Siech, Walter Hofmann, Jochen H.H. Ehrich, Walter G. Guder, et al.

  • 4.7 Neurologische Erkrankungen

    by Manfred Wolfgang Wick, Hans Jürgen Kühn, Markus Otto, Hela-Felicitas Petereit, Hayrettin Tumani, Manfred Uhr, Brigitte Wildemann

  • Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis

    by Hela-Felicitas Petereit, Dirk Reske, Hayrettin Tumani, Sven Jarius, F. Markus Leweke, Dirk Woitalla, Hans-Walter Pfister, Andrea Rubbert

    Neurosarcoidosis (NS) represents an important differential diagnosis of multiple sclerosis (MS). However, thus far no reliable laboratory marker of neurosarcoidosis exists. The objective of this study was to evaluate whether cerebrospinal fluid (CSF) levels of soluble interleukin 2 receptor (sIL2-R) distinguish NS and other inflammatory disorders of the central nervous system. For this purpose, 139 paired CSF and serum samples from 11 patients with NS, 21 with MS, 10 with CNS vasculitis, 22 with bacterial meningitis, 17 with viral meningitis/encephalitis, seven with neurotuberculosis, and 18 healthy donors were assessed for sIL2-R using an enzyme-linked immunosorbent assay. We found that sIL2-R CSF levels above 150 pg/ml identified untreated NS patients with an overall accuracy of 93% against a group of non-infectious CNS-diseases. Furthermore, an increase in sIL2-R in the CSF was associated with and preceded the outbreak of new neurological symptoms. In conclusion, these findings suggest that sIL2-R measurement in the CSF may be a valuable tool in the diagnosis and follow-up of patients with suspected and proven neurosarcoidosis.


  • Prädiktoren der Interferon-β-1b-Therapie-Response

    by H.-F. Petereit, W. Möller-Hartmann, D. Reske, M. Schröter, E. Stadler, R. Remus, M. Sailer, C. Hardt

  • Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

    by Hf Petereit, A Rubbert-Roth

    Background Rituximab, a monoclonal antibody against the B-cell-specific surface protein CD20, is being evaluated for treatment of multiple sclerosis and neuromyelitis optica. Both diseases are restricted to the brain and cerebrospinal fluid (CSF). Whereas the ability of rituximab to deplete B cells in peripheral blood and tissue is well known, little information is available about the ability of rituximab to penetrate the barriers separating brain and CSF from the serum compartment. Objective To measure rituximab levels in serum and CSF of rituximab-treated patients and correlate them with CSF and response markers. Methods Fourteen paired serum/CSF samples of patients with autoimmune nervous system disorder were analyzed for up to 43 weeks after rituximab application. Results Rituximab remains detectable within the CSF after i.v. application for up to 24 weeks. Furthermore, levels of rituximab in CSF correlate significantly with the integrity of the blood CSF barrier.


  • Rituximab in a patient with multiple sclerosis - effect on B cells, plasma cells and intrathecal IgG synthesis

    by H. F. Petereit, W. Moeller-Hartmann, D. Reske, A. Rubbert

    To study the time course of immunoglobulin, B and plasma cells in the blood and cerebrospinal fluid (CSF) before and during rituximab treatment in a patient with severe relapsing-remitting multiple sclerosis (MS) in relation to clinical and MRI findings. Immunoglobulins in the CSF were measured by nephelometry and detected by isoelectrical focussing. CSF and blood cell subtypes from seven time points were analysed by flow cytometry. Treatment with rituximab induced a dramatic and sustained improvement in clinical and MRI findings over a follow-up period of 20 months. By contrast, the initially completely suppressed B and plasma cells in both the blood and CSF reappeared after 5 and 10 months, CSF cells being the first to reappear. Interestingly, intrathecal IgG synthesis persisted throughout the study period. Although highly effective in this case, the clinical effect in larger series and the mechanism of rituximab in MS deserves further evaluation.